Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 5Fallopian Tube Neoplasms 5Breast Neoplasms 5Endometrial Neoplasms 4Neoplasms 3Uterine Cervical Neoplasms 2Prostatic Neoplasms 2Carcinoma, Ovarian Epithelial 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumor, Unspecified, Adult 1Solid Tumor 1Small Cell Lung Carcinoma 1Prostate Cancer Metastatic 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Metastatic Castration-resistant Prostate Cancer 1Mesothelioma, Malignant 1Leiomyosarcoma 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Adenocarcinoma, Clear Cell 1Adenocarcinoma of the Oesophagus 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1ATM Gene Mutation 1

Interventions

rucaparib 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × ATM Gene Mutation × rucaparib × Clear all
NCT03442556 2025-06-12

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

University of Washington

Phase 2 Terminated
18 enrolled
Genitourinary

ATM Gene Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡